Skip to main content

Table 3 Curative study

From: Evaluation of anti-malarial potency of new pyrazole-hydrazine coupled to Schiff base derivatives

Treatment

Dose (mg/kg)

Parasitaemia count

Day 0

Day 1

Day 2

Day 3

Control

6.76 ± 0.29

13.60 ± 0.62#

14.39 ± 0.27#

15.02 ± 0.53#

BePINH

2.5

7.70 ± 2.76

7.53 ± 2.49*

6.61 ± 1.63*

6.33 ± 2.80*

10

8.26 ± 2.40

6.56 ± 2.35*

5.58 ± 1.79*

5.04 ± 2.35*

15

6.63 ± 2.02

6.28 ± 1.85*

5.53 ± 1.63*

2.93 ± 1.73*

BePBeH

2.5

7.83 ± 2.58

7.79 ± 2.06

7.07 ± 1.65*

6.64 ± 2.45*

10

6.63 ± 2.10

6.77 ± 1.92*

6.56 ± 2.11*

5.31 ± 1.01*

15

6.35 ± 2.02

6.69 ± 1.77*

5.58 ± 1.55*

2.98 ± 0.57*

ACT

5

7.44 ± 2.01

6.66 ± 2.05*

3.03 ± 2.22*

1.40 ± 1.93*#

  1. Each value represents the mean ± S.E.M, n = 5
  2. ACT artemisinin-based Combination Therapy
  3. *,#p < 0.05 compared with control and Day 0, respectively (One-way ANOVA; Dunnett’s post hoc)